Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
SummaryWith paid stock promotion CBMG has achieved an unsustainable $500m valuation, and with $20m in stock sold and insiders stock registered to sell, I expect CBMG will continue to collapse.
CBMG “Car-T” technology was acquired for $1.8m, has experienced patient deaths and is worthless. CBMG recent R&D of just $4.9m makes the $500m valuation clearly absurd.
CBMG founders face dishonesty allegations, are […]